teclistamab, teclistamab, JNJ-79635322, JNJ-79635322
79635322MMY3001
Phase 3 small_molecule active
Quick answer
teclistamab, teclistamab, JNJ-79635322, JNJ-79635322 for Relapsed or Refractory Multiple Myeloma is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active